We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi-Regeneron Sarilumab Approved in Canada for Arthritis
Read MoreHide Full Article
Sanofi (SNY - Free Report) and Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that their pipeline candidate, sarilumab, has been approved in Canada for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying anti-rheumatic drugs (DMARDs). Sarilumab, to be marketed under the trade name Kevzara, is expected to be available to patients in Canada soon.
Sarilumab is still under review in the U.S and the EU, with regulatory decisions expected later this year.
The Canadian approval was supported by data from the global SARIL-RA clinical study, conducted in approximately 2,900 adults with moderate-to-severely active RA. Kevzara demonstrated clinically meaningful improvements, both as monotherapy and in combination with conventional DMARDs, including methotrexate.
Shares of Sanofi have significantly outperformed the Zacks classified Large Cap Pharma industry in the last six months. The stock lost 1.9% during the period, while the industry registered a decline of 13.9%.
We note that in Oct 2016, the companies got a Complete Response Letter (CRL) from the FDA for sarilumab. While the CRL did not raise any issues regarding sarilumab’s efficacy or safety, the agency cited certain deficiencies observed during a routine good manufacturing practice inspection of the Sanofi Le Trait facility in France where sarilumab is filled and finished. Sanofi has submitted a comprehensive corrective action plan to the FDA and is working on implementing corrective actions.
Resubmission of sarilumab’s Biologics License Application (BLA) to the FDA is expected in the first quarter of 2017. The resubmission, however, depends on successful completion of an inspection of the Le Trait facility by the FDA, with an anticipated action date in the second quarter of 2017.
Meanwhile, the European Medicines Agency accepted the companies’ marketing authorisation application for sarilumab for review in Jul 2016.
Note that Pfizer, Inc.’s (PFE - Free Report) Xeljanz is already approved for the treatment of moderate-to-severely active RA in patients who respond inadequately or are intolerant to methotrexate. Other drugs approved for RA include Roche Holding AG’s (RHHBY - Free Report) Actemra and Bristol-Myers Squibb’s Orencia.
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi-Regeneron Sarilumab Approved in Canada for Arthritis
Sanofi (SNY - Free Report) and Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that their pipeline candidate, sarilumab, has been approved in Canada for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying anti-rheumatic drugs (DMARDs). Sarilumab, to be marketed under the trade name Kevzara, is expected to be available to patients in Canada soon.
Sarilumab is still under review in the U.S and the EU, with regulatory decisions expected later this year.
The Canadian approval was supported by data from the global SARIL-RA clinical study, conducted in approximately 2,900 adults with moderate-to-severely active RA. Kevzara demonstrated clinically meaningful improvements, both as monotherapy and in combination with conventional DMARDs, including methotrexate.
Shares of Sanofi have significantly outperformed the Zacks classified Large Cap Pharma industry in the last six months. The stock lost 1.9% during the period, while the industry registered a decline of 13.9%.
We note that in Oct 2016, the companies got a Complete Response Letter (CRL) from the FDA for sarilumab. While the CRL did not raise any issues regarding sarilumab’s efficacy or safety, the agency cited certain deficiencies observed during a routine good manufacturing practice inspection of the Sanofi Le Trait facility in France where sarilumab is filled and finished. Sanofi has submitted a comprehensive corrective action plan to the FDA and is working on implementing corrective actions.
Resubmission of sarilumab’s Biologics License Application (BLA) to the FDA is expected in the first quarter of 2017. The resubmission, however, depends on successful completion of an inspection of the Le Trait facility by the FDA, with an anticipated action date in the second quarter of 2017.
Meanwhile, the European Medicines Agency accepted the companies’ marketing authorisation application for sarilumab for review in Jul 2016.
Note that Pfizer, Inc.’s (PFE - Free Report) Xeljanz is already approved for the treatment of moderate-to-severely active RA in patients who respond inadequately or are intolerant to methotrexate. Other drugs approved for RA include Roche Holding AG’s (RHHBY - Free Report) Actemra and Bristol-Myers Squibb’s Orencia.
Sanofi Price
Sanofi Price | Sanofi Quote
Zacks Rank
Sanofi currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>